Larvol Delta - A-Randomized-Phase-2-Trial-of-Nivolumab-Relatlimab-Plus-Ipilimumab-vs-Nivolumab-Plus-Ipilimumab-in-Firstline-Advanced-Renal-Cell-Carcinoma-RCC

pumitamig (BNT327) - BioNTech, BMS

elfetabart drozuntecan (BNT324) - BioNTech

https://medicalxpress.com/news/2026-09-pumitamig-ifinatamab-deruxtecan-early-small.html

Sep 12, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next